Recent meaningful negative changes in fundamentals have impacted ADMA Biologics Inc (NASDAQ: ADMA): the stock’s power rating fell below 50, significant quarterly earnings deceleration occurred, and the consensus estimate for December, 2025 decreased significantly.
ADMA Biologics Inc (NASDAQ: ADMA) suffers from notable negative changes in investment behavior: the stock fell on very heavy volume.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
ADMA Biologics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. ADMA Biologics has a slightly positive Appreciation Score of 69 but a poor Power Rating of 26, and the Neutral Value Trend Rating results.
Recent Price Action
ADMA Biologics Inc (NASDAQ: ADMA) stock closed at $15.91 on 9/19/25 after a modest decline of -1.5%. Moreover, exceptionally high trading volume at 258% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -1.2% during the last week.
Be the first to comment